Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Conditions: Constitutional Mismatch Repair Deficiency Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Lynch Syndrome; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Primary Central Nervous System Neoplasm; Refractory Lympho ma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Primary Central Nervous System Neoplasm; Xeroderma Pigmentosum Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | Cancer in Adolescents | Children | Gastroschisis Repair | Genetics | Immunotherapy | Lymphoma | Neuroblastoma | Neurology | Primary CNS Lymphoma | Research | Study | Yervoy